Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine TumorsJonathan Strosberg, Eric P. Krenning, Ghassan El‐Haddad et al.|New England Journal of Medicine|2017Cited by 3.2k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and SurvivalDik J. Kwekkeboom, Eric P. Krenning, Casper H.J. van Eijck et al.|Journal of Clinical Oncology|2008Cited by 1.4k
Radiolabeled Somatostatin Analog [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]Octreotate in Patients With Endocrine Gastroenteropancreatic TumorsDik J. Kwekkeboom, Eric P. Krenning, Jaap J.M. Teunissen et al.|Journal of Clinical Oncology|2005Cited by 659
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine TumorsTessa Brabander, Dik J. Kwekkeboom, Wouter A. van der Zwan et al.|Clinical Cancer Research|2017Cited by 604
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid ImagingAnders Sundin, Rudolf Arnold, Éric Baudin et al.|Neuroendocrinology|2017Cited by 495